- Home
- EDTK vs PHIO Comparison
EDTK vs PHIO Comparison
Compare EDTK & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDTK
- PHIO
- Stock Information
- Founded
- EDTK 2013
- PHIO 2011
- Country
- EDTK China
- PHIO United States
- Employees
- EDTK N/A
- PHIO N/A
- Industry
- EDTK Other Consumer Services
- PHIO Biotechnology: Pharmaceutical Preparations
- Sector
- EDTK Real Estate
- PHIO Health Care
- Exchange
- EDTK Nasdaq
- PHIO Nasdaq
- Market Cap
- EDTK 14.3M
- PHIO 11.9M
- IPO Year
- EDTK 2020
- PHIO N/A
- Fundamental
- Price
- EDTK $0.93
- PHIO $2.32
- Analyst Decision
- EDTK
- PHIO Strong Buy
- Analyst Count
- EDTK 0
- PHIO 2
- Target Price
- EDTK N/A
- PHIO $9.00
- AVG Volume (30 Days)
- EDTK 8.7K
- PHIO 200.0K
- Earning Date
- EDTK 08-18-2025
- PHIO 08-13-2025
- Dividend Yield
- EDTK N/A
- PHIO N/A
- EPS Growth
- EDTK N/A
- PHIO N/A
- EPS
- EDTK N/A
- PHIO N/A
- Revenue
- EDTK $624,365.00
- PHIO N/A
- Revenue This Year
- EDTK N/A
- PHIO N/A
- Revenue Next Year
- EDTK N/A
- PHIO N/A
- P/E Ratio
- EDTK N/A
- PHIO N/A
- Revenue Growth
- EDTK N/A
- PHIO N/A
- 52 Week Low
- EDTK $0.80
- PHIO $0.97
- 52 Week High
- EDTK $1.27
- PHIO $9.79
- Technical
- Relative Strength Index (RSI)
- EDTK 54.77
- PHIO 55.02
- Support Level
- EDTK $0.87
- PHIO $2.33
- Resistance Level
- EDTK $0.95
- PHIO $2.62
- Average True Range (ATR)
- EDTK 0.05
- PHIO 0.15
- MACD
- EDTK 0.01
- PHIO 0.00
- Stochastic Oscillator
- EDTK 100.00
- PHIO 65.69
About EDTK Skillful Craftsman Education Technology Limited
Skillful Craftsman Education Technology Ltd provides online education and technology services in China. The services comprises of two aspects - Online vocational training and Virtual simulation experimental training. It covers a wide range of subjects, including mechanics, electronics, auto repair and construction. Majority of its revenues are generated from the People's Republic of China.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.